Targeting cytotoxic T lymphocytes for cancer immunotherapy

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 817-821

  Maher, J ^a,b   Davies, E T ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adoptive immunotherapy; CTL; Gene therapy; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; GENE THERAPY; GENE TRANSFER; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR IMMUNOLOGY; VACCINATION;

GENE TRANSFER TECHNIQUES; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4644289585     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602022     Document Type: Short Survey

References (35)

1. Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26: 2304-2309
2. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I, Sadelain M (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9: 279-286, doi:10.1038/nm827
3. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB (1998) Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187: 1395-1402
4. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5: 7-10, doi:10.1038/ni0104-7
5. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859
6. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7: 1127-1135
7. Coulie PG, van der Bruggen P (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15: 131-137, doi:10.1016/S0952-7915(03)00009-8
8. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854
9. Eshhar Z (1997) Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 45: 131-136
10. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3: 630-641, doi:10.1038/nri1150
11. Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113
12. Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161: 2791-2797
13. Gilboa E (1999) How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48: 382-385
14. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1: 123-127
15. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7: 1118-1122, doi:10.1038/nm1001-1118
16. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169: 575-580
17. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163, doi: 10.1182/blood-2002-04-1041
18. Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484
19. Kohn DB, Sadelain M, Glorioso JC (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3: 477-488, doi:10.1038/nrc1122
20. Lanzavecchia A (1998) Licence to kill. Nature 393: 413-414
21. Latouche JB, Sadelain M (2000) Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18: 405-409, doi:10.1038/74455
22. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR/CD28 receptor. Nat Biotechnol 20: 70-75, doi:10.1038/nbt0102-70
23. Morris EC, Bendle GM, Stauss HJ (2003) Prospects for immunotherapy of malignant disease. Clin Exp Immunol 131: 1-7, doi:10.1046/j.1365-2249.2003. 02055.x
24. Nelson BH (2004) IL-2, regulatory T cells, and tolerance. J Immunol 172: 3983-3988
25. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9: 1413-1417, doi:10.1038/nm949
26. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63: 4095-4100
27. Romieu R, Baratin M, Kayibanda M, Lacabanne V, Ziol M, Guillet JG, Viguier M (1998) Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J Immunol 161: 5133-5137
28. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE (2001) Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol 258: 221-229
29. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166
30. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK (2002) Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99: 2009-2016
31. Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE (2003) T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 88: 1119-1127, doi:10.1038/sj.bjc.6600857
32. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide - MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571
33. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188: 51-64
34. Whelan M, Whelan J, Russell N, Dalgleish A (2003) Cancer immunotherapy: an embarrassment of riches? Drug Discov Today 8: 253-258, doi:10.1016/S1359- 6446(03)02633-3
35. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu Y-X (2004) Priming of naïve T cells inside tumors leads to eradication of established tumors. Nat Immunol 5: 141-149, doi:10.1038/ni1029